-
Loading metrics
First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
- Mattias Neyt,
- Joan Vlayen,
- Stephan Devriese,
- Cécile Camberlin
x
- Published: April 9, 2018
- https://doi.org/10.1371/journal.pone.0195134
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
Loading metrics